Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study

Although the treatment of individual patients is largely dependent on their attitude toward the risk of disease progression and blindness, the treatment of those patients with IOP of ≥24 mm Hg and a ≥2% annual risk of the development of glaucoma is likely to be cost-effective. Delay of treatment for all people with ocular hypertension until glaucoma-related symptoms are present appears to be unnecessarily conservative.